Liposomal Amphotericin B and HIV-Associated Visceral Leishmaniasis: Concerns about Nephrotoxicity and Administration Schedule

Author： Sergio Sabbatani Roberto Manfredi Ginevra Marinacci Michele Pavoni Michele Nafissi Francesco Chiodo

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.25, Iss.1, 2005-01, pp. : 85-87

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Liposomal Amphotericin B: Therapeutic Use in the Management of Fungal Infections and Visceral Leishmaniasis

By Coukell A.J. Brogden R.N.

Drugs, Vol. 55, Iss. 4, 1998-04 ,pp. : 585-612

Adis International

Access to resources Recommend Favorite

Liposomal amphotericin B as a treatment for human leishmaniasis

By Balasegaram Manica

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 4, 2012-12 ,pp. : 493-510

Informa Healthcare

Access to resources Recommend Favorite

Amphotericin B Lipid Complex: In Visceral Leishmaniasis

By Goldsmith David R. Perry Caroline M.

Drugs, Vol. 64, Iss. 17, 2004-01 ,pp. : 1905-1911

Adis International

Access to resources Recommend Favorite

An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB)

By Patel Gourang

Journal of Medical Toxicology, Vol. 7, Iss. 1, 2011-03 ,pp. : 12-15

Springer Publishing Company

Access to resources Recommend Favorite

Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

By Gupta Swati Dube Anuradha Vyas Suresh P.

Journal of Drug Targeting, Vol. 15, Iss. 6, 2007-07 ,pp. : 437-444

Informa Healthcare

Access to resources Recommend Favorite